Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs is dedicated to supporting the development of anti-GYPA CAR-T therapy. We provide not only a comprehensive series of GYPA molecular-related CAR-T products but also customized CAR-T cell development services. Our extensive range of anti-GYPA CAR-T products and customized services enable researchers to advance their innovative treatments and make a significant impact on the field of CAR-T therapy.
Glycophorins A (GYPA) and B (GYPB) are major sialoglycoproteins of the human erythrocyte membrane which bear the antigenic determinants for the MN and Ss blood groups. In addition to the M or N and S or s antigens that commonly occur in all populations, about 40 related variant phenotypes have been identified. These variants include all the variants of the Miltenberger complex and several isoforms of Sta, as well as Dantu, Sat, He, Mg, and deletion variants Ena, SsU, and Mk. Mutations in GYPA can lead to various forms of anemia and other symptoms, including sickle cell anemia and thalassemia. Moreover, GYPA mutations are associated with an increased susceptibility to certain types of malignancies.
Fig.1 Schematic of GYPA.1
Ovarian cancer
Colorectal cancer
Breast cancers
Prostate cancer
Lung cancer
Anti-GYPA CAR-T Expression Test
The Anti-GYPA CAR-T Expression Test is designed to monitor the expression of the anti-GYPA CAR-T receptor and its components in T cells. This test helps to ensure that the anti-GYPA CAR-T cells express the appropriate receptors and molecules at the correct levels, which is crucial for their function and survival. We analyze anti-GYPA CAR expression by different detection methods using flow cytometry, western blot, and qPCR.
Anti-GYPA CAR-T Proliferation Test
The Anti-GYPA CAR-T Proliferation Test evaluates the ability of anti-GYPA CAR-T cells to proliferate and expand in response to specific stimuli. This test is crucial for determining the potential of anti-GYPA CAR-T cells to generate a sufficient number of effector cells for therapeutic applications.
Anti-GYPA CAR-T Cytokine Release Test
The Anti-GYPA CAR-T Cytokine Release Test assesses the ability of anti-GYPA CAR-T cells to produce and release cytokines in response to specific stimuli. By measuring the level of cytokines released by anti-GYPA CAR-T cells, we can evaluate their immune-stimulating potential and assess their suitability and safety for use in therapeutic applications.
Anti-GYPA CAR-T In Vitro Cytotoxicity Assay
The Anti-GYPA CAR-T Cytotoxicity Test is designed to measure the ability of anti-GYPA CAR-T cells to target and eliminate cancer cells expressing GYPA. This test helps to evaluate the specificity and potency of anti-GYPA CAR-T cells against target cells. By analyzing the rate of target cell death induced by anti-GYPA CAR-T cells, we can assess the cytotoxic potential of these cells and ensure that they selectively target cancer cells without causing unnecessary harm to healthy tissues.
We provide in vivo assays to evaluate the therapeutic potential and safety of anti-GYPA CAR-T cells in a living organism. These assays typically involve the administration of anti-GYPA CAR-T cells to animal models, such as mice or rats, and monitoring their physiological and behavioral responses. By conducting these assays, we can determine the efficacy of anti-GYPA CAR-T cells in targeting specific diseases and assess any potential adverse effects.
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-0120ZP1347 | Anti-GYPA (NNA7) h(CD28-CD3ζ) CAR, pCDCAR1 | Mouse | NNA7 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| XS-0622-ZP3263 | Anti-GYPA h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
| XS-0822-YF495 | Anti-Human GYPA (XW-495) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-495 | Human | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF496 | Anti-Human GYPA (XW-496) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-496 | Human | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF497 | Anti-Human GYPA (XW-497) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-497 | Mouse | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF498 | Anti-Human GYPA (XW-498) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-498 | Mouse | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF499 | Anti-Mouse GYPA (XW-499) m(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-499 | Mouse | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF500 | Anti-Mouse GYPA (XW-500) m(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-500 | Mouse | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1415 | Anti-Human GYPA (XW-495) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-495 | Human | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1416 | Anti-Human GYPA (XW-496) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-496 | Human | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1417 | Anti-Human GYPA (XW-497) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-497 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1418 | Anti-Human GYPA (XW-498) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-498 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1419 | Anti-Mouse GYPA (XW-499) m(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-499 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1420 | Anti-Mouse GYPA (XW-500) m(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-500 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF2335 | Anti-Human GYPA (XW-495) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-495 | Human | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF2336 | Anti-Human GYPA (XW-496) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-496 | Human | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF2337 | Anti-Human GYPA (XW-497) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-497 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF2338 | Anti-Human GYPA (XW-498) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-498 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF2339 | Anti-Mouse GYPA (XW-499) m(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-499 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF2340 | Anti-Mouse GYPA (XW-500) m(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-500 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
